Literature DB >> 24191714

Promoter hypermethylation of BCL6B gene is a potential plasma DNA biomarker for gastric cancer.

Qingfan Yang1, Jing Gao, Lixia Xu, Zhirong Zeng, Joseph J Y Sung, Jun Yu.   

Abstract

We previously showed that BCL6B acts as a tumor suppressor in gastric cancer and up to 66% gastric cancer patients have promoter hypermethylation in tumor tissues. We aimed to evaluate the feasibility of detecting BCL6B methylation in plasma DNA as a potential biomarker for gastric cancer. Hypermethylation of the CpG islands in BCL6B promoter was detected in 42.5% (17/40) plasma DNA samples from gastric cancer patients, while no methylation was found in the plasma DNA of healthy controls (p < 0.001). BCL6B methylation may serve as a novel potential non-invasive plasma biomarker for the detection of gastric cancer.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24191714     DOI： 10.3109/1354750X.2013.853839

Source DB:  PubMed          Journal:  Biomarkers        ISSN： 1354-750X            Impact factor:   2.658


  14 in total

1.  Epigenetic silencing BCL6B induced colorectal cancer proliferation and metastasis by inhibiting P53 signaling.

Authors:  Sui Hu; Baoping Cao; Meiying Zhang; Enqiang Linghu; Qimin Zhan; Malcolm V Brock; James G Herman; Gaoping Mao; Mingzhou Guo
Journal:  Am J Cancer Res       Date:  2015-01-15       Impact factor: 6.166

Review 2.  How to stomach an epigenetic insult: the gastric cancer epigenome.

Authors:  Nisha Padmanabhan; Toshikazu Ushijima; Patrick Tan
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-05-17       Impact factor: 46.802

Review 3.  Challenges of deciphering gastric cancer heterogeneity.

Authors:  Petra Hudler
Journal:  World J Gastroenterol       Date:  2015-10-07       Impact factor: 5.742

4.  Epigenetic silencing of BCL6B inactivates p53 signaling and causes human hepatocellular carcinoma cell resist to 5-FU.

Authors:  Xin Li; Jie Yu; Malcolm V Brock; Qian Tao; James G Herman; Ping Liang; Mingzhou Guo
Journal:  Oncotarget       Date:  2015-05-10

5.  BCL6B expression in hepatocellular carcinoma and its efficacy in the inhibition of liver damage and fibrogenesis.

Authors:  Weilin Wang; Pengfei Huang; Panyisha Wu; Rong Kong; Jiang Xu; Lufei Zhang; Qifan Yang; Qingsong Xie; Linshi Zhang; Xiaohu Zhou; Linghui Chen; Haiyang Xie; Lin Zhou; Shusen Zheng
Journal:  Oncotarget       Date:  2015-08-21

Review 6.  Diagnostic and prognostic value of circulating tumor DNA in gastric cancer: a meta-analysis.

Authors:  Yunhe Gao; Kecheng Zhang; Hongqing Xi; Aizhen Cai; Xiaosong Wu; Jianxin Cui; Jiyang Li; Zhi Qiao; Bo Wei; Lin Chen
Journal:  Oncotarget       Date:  2017-01-24

7.  The survival decrease in gastric cancer is associated with the methylation of B-cell CLL/lymphoma 6 member B promoter.

Authors:  Jingyu Deng; Han Liang; Qiuping Dong; Yachao Hou; Xingming Xie; Jun Yu; Daiming Fan; Xishan Hao
Journal:  Open Biol       Date:  2014-07       Impact factor: 6.411

8.  BCL6B suppresses proliferation and migration of colorectal carcinoma cells through inhibition of the PI3K/AKT signaling pathway.

Authors:  Yue Gu; Aifang Li; Hui Sun; Xueru Li; He Zha; Jiali Zhao; Jiaqing Xie; Zongyue Zeng; Lan Zhou
Journal:  Int J Mol Med       Date:  2018-02-01       Impact factor: 4.101

9.  From Anti-EBV Immune Responses to the EBV Diseasome via Cross-reactivity.

Authors:  Darja Kanduc; Yehuda Shoenfeld
Journal:  Glob Med Genet       Date:  2020-08-31

10.  Integrated analysis of DNA methylation profiling and gene expression profiling identifies novel markers in lung cancer in Xuanwei, China.

Authors:  Juan Wang; Yong Duan; Qing-He Meng; Rong Gong; Chong Guo; Ying Zhao; Yanliang Zhang
Journal:  PLoS One       Date:  2018-10-04       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.